Showing results (131-140 of 639) with videos related to
Sort By:
Pageof 64
Bulletin Du Cancer|February 4, 2005
Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)Olivier Rixe, Michel Gatineau, Eric Jauffret, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung CancerJosette Biya, Caroline Caramella, Colin R Lindsay, et al.Nature Reviews. Clinical Oncology|August 16, 2018
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Gonzalo Recondo, Francesco Facchinetti, Ken A Olaussen, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patientMaria Gion, Jordi Remon, Caroline Caramella, et al.European Radiology|November 22, 2019
Safety and effectiveness of cervical vertebroplasty: report of a large cohort and systematic reviewFrédéric Clarençon, Robert Fahed, Evelyne Cormier, et al.Molecular and Clinical Oncology|June 23, 2016
Disseminated intravascular coagulation following administration of sunitinibAnaëlle Olivo, Nicolas Noël, Benjamin Besse, et al.Investigational New Drugs|February 20, 2016
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinibLinda Mahjoubi, Anas Gazzah, Benjamin Besse, et al.Cancer Treatment Reviews|September 26, 2020
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history beginsJordi Remon, Lizza E L Hendriks, Andres F Cardona, et al.Progress in Retinal and Eye Research|September 20, 2024
Ocular adverse events associated with antibody-drug conjugates used in cancer: Focus on pathophysiology and management strategiesEric E Gabison, Antoine Rousseau, Marc Labetoulle, et al.Bulletin Du Cancer|March 31, 2015
[Second generation ALK inhibitors in non-small cell lung cancer: systemic review]Marie Viala, Solenn Brosseau, David Planchard, et al.Pageof 64